WO2001022991A1 - Traitement a l'acth de patients recevant des steroides et des statines - Google Patents
Traitement a l'acth de patients recevant des steroides et des statines Download PDFInfo
- Publication number
- WO2001022991A1 WO2001022991A1 PCT/SE2000/001880 SE0001880W WO0122991A1 WO 2001022991 A1 WO2001022991 A1 WO 2001022991A1 SE 0001880 W SE0001880 W SE 0001880W WO 0122991 A1 WO0122991 A1 WO 0122991A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acth
- patient
- statins
- therapy
- fragments
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title claims abstract description 7
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims abstract description 15
- 229960000258 corticotropin Drugs 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 239000012634 fragment Substances 0.000 claims abstract description 10
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims abstract description 6
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract 6
- 238000004519 manufacturing process Methods 0.000 claims abstract 3
- 101800000414 Corticotropin Proteins 0.000 claims description 14
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 235000019625 fat content Nutrition 0.000 claims description 4
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 claims 4
- 239000003246 corticosteroid Substances 0.000 claims 4
- 229960001334 corticosteroids Drugs 0.000 claims 4
- 239000005022 packaging material Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract description 11
- 150000003431 steroids Chemical class 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 description 8
- 238000008214 LDL Cholesterol Methods 0.000 description 3
- ZOEFCCMDUURGSE-SQKVDDBVSA-N cosyntropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 ZOEFCCMDUURGSE-SQKVDDBVSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 108010071339 adrenocorticotropin zinc Proteins 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001000 lipidemic effect Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- A61K38/35—Corticotropin [ACTH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Definitions
- the active ingredient of the therapeutic composition is ACTH including fragments thereof.
- fragments as used herein means ACTH from which amino acids in the sequence have been “cut off” to such an extent that the therapeutic effect of the fragments is at least equal to that of the ACTH.
- Synacthen Ciba-Geigy, Basel, Switzerland
- 1-24 N-terminal fragment of ACTH.
- preparations comprising fragments of ACTH are commer- cially available. The selection thereof for the purpose of the invention is within the purview of one skilled in the art, i.e. a physician.
- the amount of the therapeutically active ingredient that is administered and the dosage regimen for treating a disease condition with the composition depends on a variety of factors, including the age, weight, sex and medical condition of the patient, the severity of the disease, the route and frequency of administration, and the particular compound employed, and thus may vary widely. Thus, a skilled physician is able to determine the appropriate dosage considering the factors mentioned above. By way of example the following treatment scheme may be mentioned:
- the preparation is Synacthen Depot, which is given by an intramuscular injection.
- Month 1 1 mg once a week
- an intramuscular injection of 1 mg ACTH, or fragments thereof, twice a week is associated with significant long-term improvements of the blood fat contents in serum in patients who are on therapy on steroids and statins.
- a preparation of ACTH or fragments thereof is injected sub- cutaneously.
- injectable preparations can contain such carriers or diluents as water, saline, dextrose, etc, which are preferable isotonic and sterile.
- a preparation of ACTH or fragments thereof is administered through the nasal route.
- the ACTH preparation is most preferably sold in a package containing a disposable syringe having said preparation present therein.
- the preparation is contained in an inhaling device such as a spray device .
- the preferred route is the intramuscular, subcutaneous and the nasal route.
- Example 1 Ten patients were studied. They were all hyper- lipidemic (LDL cholesterol>3.5 mmol/L) in spite of ongoing treatment with Simvastatin (Zocord) at the maximal recommended dose i.e., 40 mg daily, and dietary advice. In all cases, the hyperlipidemia was probably primary since there was no, evidence of secondary influence on the lipoprotein metabolism (such as renal or endocrinological disease) .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La présente invention concerne une méthode de traitement de patient en cours de soin avec des stéroïdes et des statines. Cette méthode consiste à administrer au patient une quantité effective, sur le plan thérapeutique, d'une composition contenant de l'ACTH ou des fragments de celle-ci. L'invention concerne aussi l'utilisation de la composition ainsi qu'un article manufacturé, contenant la composition thérapeutique, utile pour mettre en oeuvre la méthode.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU76975/00A AU7697500A (en) | 1999-09-29 | 2000-09-29 | Acth treatment of steroid- and statin-treated patients |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15659099P | 1999-09-29 | 1999-09-29 | |
| US60/156,590 | 1999-09-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001022991A1 true WO2001022991A1 (fr) | 2001-04-05 |
Family
ID=22560203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/SE2000/001880 WO2001022991A1 (fr) | 1999-09-29 | 2000-09-29 | Traitement a l'acth de patients recevant des steroides et des statines |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU7697500A (fr) |
| WO (1) | WO2001022991A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009040032A3 (fr) * | 2007-09-11 | 2009-05-22 | Mondobiotech Lab Ag | Utilisation d'un peptide en tant qu'agent thérapeutique |
-
2000
- 2000-09-29 WO PCT/SE2000/001880 patent/WO2001022991A1/fr active Application Filing
- 2000-09-29 AU AU76975/00A patent/AU7697500A/en not_active Abandoned
Non-Patent Citations (8)
| Title |
|---|
| A.-L. BERG ET AL.: "ACTH 1-24 decreases hepatic lipase activities and low density lipoprotein concentrations in healthy men", JOURNAL OF INTERNAL MEDICINE, vol. 229, 1991, pages 201 - 203, XP002935312 * |
| A.-L. BERG ET AL.: "Regulation of hepatic lipase secretion from Hep G2 cells by ACTH and corticosteroids", HORM. METAB. RES., vol. 29, 1997, pages 475 - 476, XP002935315 * |
| BERG ANNA-LENA ET AL.: "ACTH revisited-potential implications for patients with renal disease", NEPHROL. DIAL. TRANSPLANT, vol. 15, July 2000 (2000-07-01), pages 940 - 942, XP002935317 * |
| BERG ANNA-LENA ET AL.: "Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy", KIDNEY INTERNATIONAL, vol. 56, October 1999 (1999-10-01), pages 1534 - 1543, XP002935316 * |
| DATABASE FILE CAPLUS [online] BERG ANNA-LENA ET AL.: "ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney desease", retrieved from 125:158195 accession no. STN International Database accession no. 1996:519022 * |
| KIDNEY INT., vol. 50, no. 2, 1996, pages 538 - 542 * |
| MARGRET ARNADOTTIR ET AL.: "Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations in hemodialysis patients", KIDNEY INTERNATIONAL, vol. 52, 1997, pages 1651 - 1655, XP002935314 * |
| MARGRET ARNADOTTIR ET AL.: "Corticotropin-induced reduction of plasma lipoprotein(a) concentrations in healthy individuals and hemodialysis patients: Relation to apolipoprotein(a) size polymorphism", METABOLISM, vol. 48, no. 3, March 1999 (1999-03-01), pages 342 - 346, XP002935313 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009040032A3 (fr) * | 2007-09-11 | 2009-05-22 | Mondobiotech Lab Ag | Utilisation d'un peptide en tant qu'agent thérapeutique |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7697500A (en) | 2001-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100343314B1 (ko) | 만성통증치료에유용한레보부피바카인 | |
| AU645874B2 (en) | Treatment for osteoporosis using growth hormone release factor (GRF) in combination with parathyroid hormone (PTH) | |
| EP0360340A1 (fr) | Composition pour administration par voie nasale contenant un peptide | |
| UA32636C2 (uk) | Засіб для зниження вмісту холестерину в сироватці крові людини | |
| NZ227857A (en) | Pharmaceutical composition of igf-i and insulin for treating or preventing secondary effects of hyperinsulinemia | |
| DK177177B1 (da) | Lindring af Peyronie's sygdom | |
| JP2011246474A (ja) | エリトロポエチン及び修飾ヘモグロビンを含んでいる医薬配合製剤 | |
| WO1996024370A1 (fr) | Solutions pharmaceutiques salines non organiques a administration endonasale d'une calcitonine | |
| AU666514B2 (en) | Method and composition for the treatment of osteoporosis | |
| CA2142455A1 (fr) | Methode de traitement general des pathologies cataboliques et des blessures aux tissus de l'organisme | |
| KR920700227A (ko) | 초고활성 인체 인슐린 동족체 | |
| WO2001022991A1 (fr) | Traitement a l'acth de patients recevant des steroides et des statines | |
| Burgess et al. | Thoracic epidural anesthesia for transsternal thymectomy in myasthenia gravis | |
| US20040242489A1 (en) | Method for improving stability of a bone-connecting implant | |
| Entezariasl et al. | Efficacy of metoclopramide and dexamethasone for postoperative nausea and vomiting: a double-blind clinical trial | |
| Hudson et al. | Darbepoetin alfa, a new therapy for the management of anemia of chronic kidney disease | |
| EP0828507A1 (fr) | Technique de traitement de la douleur | |
| CA2664300C (fr) | Agent de prevention de l'apparition d'une dystrophie sympathique reflexe apres une attaque | |
| JP2002536337A (ja) | 麻酔の調節 | |
| US5725860A (en) | Method for reducing the risk of developing diabetes | |
| WO1997003689A1 (fr) | Procede de traitement de l'epilepsie au moyen du facteur neurotrophique derive du cerveau | |
| RU93008441A (ru) | Способ длительной антистрессорной терапии у хирургических больных | |
| US20020147137A1 (en) | Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid | |
| WO2024042518A1 (fr) | Antagoniste du récepteur glp-1 et ses procédés d'utilisation | |
| West et al. | Ankylosing spondylitis and prolonged ACTH therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |